Welcome to Paid Research Studies


Browse Locations ... United States» ... California» ... Orange County





  • Condition:   Solid Tumor
    Interventions:   Drug: Bevacizumab;   Drug: Cyclophosphamide;   Drug: Valproic Acid;   Drug: Temsirolimus
    Sponsors:   Miller Children's & Women's Hospital Long Beach ;   Children’s Hospital of Orange County
    Recruiting - verified May 2015

  • Conditions:   Sly Syndrome;   MPS VII;   Mucopolysaccharidosis;   Mucopolysaccharidosis VII
    Intervention:   Drug: UX003
    Sponsor:   Ultragenyx Pharmaceutical Inc
    Not yet recruiting - verified April 2015

  • Condition:   Complex Regional Pain Syndrome, Type I
    Interventions:   Drug: Placebo;   Drug: Neridronic acid 62.5 mg
    Sponsor:   Grünenthal GmbH
    Recruiting - verified May 2015

  • Conditions:   Metastatic Ewing Sarcoma;   Metastatic Malignant Neoplasm in the Bone;   Metastatic Malignant Neoplasm in the Bone Marrow;   Metastatic Malignant Neoplasm in the Lung;   Metastatic Peripheral Primitive Neuroectodermal Tumor of Bone;   Peripheral Primitive Neuroectodermal Tumor of Soft Tissues
    Interventions:   Drug: Cyclophosphamide;   Drug: Doxorubicin Hydrochloride;   Drug: Etoposide;   Radiation: External Beam Radiation Therapy;   Biological: Ganitumab;   Drug: Ifosfamide;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Radiation: Stereotactic Radiosurgery;   Procedure: Therapeutic Surgical Procedure;   Drug: Vincristine Sulfate
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified December 2014

  • Conditions:   Childhood Solid Neoplasm;   Recurrent Childhood Hodgkin Lymphoma;   Recurrent Childhood Non-Hodgkin Lymphoma;   Recurrent Childhood Rhabdomyosarcoma;   Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   Recurrent Neuroblastoma;   Recurrent Osteosarcoma;   Refractory Childhood Hodgkin Lymphoma;   Refractory Non-Hodgkin Lymphoma
    Interventions:   Biological: Ipilimumab;   Other: Laboratory Biomarker Analysis;   Biological: Nivolumab;   Other: Pharmacological Study
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified April 2015

  • Condition:   Acute Lymphoblastic Leukemia (ALL)
    Interventions:   Drug: Carfilzomib;   Drug: Dexamethasone;   Drug: Mitoxantrone;   Drug: PEG-asparaginase;   Drug: Vincristine;   Drug: Intrathecal (IT) Methotrexate;   Drug: Intrathecal Triple Therapy (Intrathecal Cytarabine, Hydrocortisone, and Methotrexate)
    Sponsors:   Onyx Therapeutics, Inc.;   Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) - Study Design & Execution Collaborator;   Innovative Therapies for Children with Cancer (ITCC) - Study Design & Execution Collaborator
    Recruiting - verified May 2015

  • Condition:   Type 2 Diabetes
    Interventions:   Drug: Saxagliptin;   Drug: Dapagliflozin;   Drug: Sitagliptin;   Drug: Placebo matching with Saxagliptin;   Drug: Placebo matching with Dapagliflozin;   Drug: Placebo matching with Sitagliptin
    Sponsors:   Bristol-Myers Squibb;   AstraZeneca
    Recruiting - verified February 2015

  • Conditions:   MPS 7;   Sly Syndrome;   Mucopolysaccharidosis;   MPS VII
    Intervention:   Drug: UX003
    Sponsor:   Ultragenyx Pharmaceutical Inc
    Recruiting - verified May 2015

  • Conditions:   Adult Fibrosarcoma;   Alveolar Soft Part Sarcoma;   Angiomatoid Fibrous Histiocytoma;   Atypical Fibroxanthoma;   Clear Cell Sarcoma of Soft Tissue;   Epithelioid Malignant Peripheral Nerve Sheath Tumor;   Epithelioid Sarcoma;   Extraskeletal Myxoid Chondrosarcoma;   Extraskeletal Osteosarcoma;   Fibrohistiocytic Neoplasm;   Glomus Tumor of the Skin;   Inflammatory Myofibroblastic Tumor;   Intimal Sarcoma;   Leiomyosarcoma;   Liposarcoma;   Low Grade Fibromyxoid Sarcoma;   Low Grade Myofibroblastic Sarcoma;   Malignant Cutaneous Granular Cell Tumor;   Malignant Peripheral Nerve Sheath Tumor;   Malignant Triton Tumor;   Mesenchymal Chondrosarcoma;   Myxofibrosarcoma;   Myxoid Chondrosarcoma;   Myxoinflammatory Fibroblastic Sarcoma;   Neoplasm With Perivascular Epithelioid Cell Differentiation;   Nerve Sheath Neoplasm;   Pericytic Neoplasm;   Plexiform Fibrohistiocytic Tumor;   Sclerosing Epithelioid Fibrosarcoma;   Stage IB Soft Tissue Sarcoma;   Stage IIB Soft Tissue Sarcoma;   Stage III Soft Tissue Sarcoma;   Stage IV Soft Tissue Sarcoma;   Synovial Sarcoma;   Unclassified Pleomorphic Sarcoma of Bone;   Undifferentiated (Embryonal) Sarcoma
    Interventions:   Drug: Doxorubicin Hydrochloride;   Drug: Ifosfamide;   Other: Laboratory Biomarker Analysis;   Drug: Pazopanib Hydrochloride;   Other: Pharmacological Study;   Radiation: Radiation Therapy;   Procedure: Therapeutic Conventional Surgery
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified April 2015

  • Conditions:   Stage II Childhood Hodgkin Lymphoma;   Stage III Childhood Hodgkin Lymphoma;   Stage IV Childhood Hodgkin Lymphoma
    Interventions:   Biological: Bleomycin Sulfate;   Drug: Brentuximab Vedotin;   Drug: Cyclophosphamide;   Drug: Doxorubicin Hydrochloride;   Drug: Etoposide;   Other: Laboratory Biomarker Analysis;   Drug: Prednisone;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Drug: Vincristine Sulfate
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified March 2015

  • Condition:   Paroxysmal Atrial Fibrillation
    Interventions:   Drug: BMS-919373;   Drug: Placebo (Matching with BMS-919373)
    Sponsor:   Bristol-Myers Squibb
    Recruiting - verified April 2015

  • Condition:   Constipation - Functional
    Intervention:   Drug: Lubiprostone
    Sponsors:   Sucampo AG;   Sucampo Pharma Americas, LLC;   Takeda
    Recruiting - verified May 2015

  • Conditions:   Adult Solid Neoplasm;   Childhood Solid Neoplasm;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Childhood Acute Lymphoblastic Leukemia;   Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
    Interventions:   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Drug: Talazoparib;   Drug: Temozolomide
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified January 2015

  • Conditions:   Adult T Acute Lymphoblastic Leukemia;   Childhood T Acute Lymphoblastic Leukemia;   Stage II Childhood Lymphoblastic Lymphoma;   Stage II Contiguous Adult Lymphoblastic Lymphoma;   Stage II Non-Contiguous Adult Lymphoblastic Lymphoma;   Stage III Adult Lymphoblastic Lymphoma;   Stage III Childhood Lymphoblastic Lymphoma;   Stage IV Adult Lymphoblastic Lymphoma;   Stage IV Childhood Lymphoblastic Lymphoma;   Untreated Adult Acute Lymphoblastic Leukemia;   Untreated Childhood Acute Lymphoblastic Leukemia
    Interventions:   Drug: Bortezomib;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Daunorubicin Hydrochloride;   Drug: Dexamethasone;   Drug: Doxorubicin Hydrochloride;   Drug: Etoposide;   Drug: Hydrocortisone Sodium Succinate;   Drug: Ifosfamide;   Other: Laboratory Biomarker Analysis;   Drug: Leucovorin Calcium;   Drug: Mercaptopurine;   Drug: Methotrexate;   Drug: Pegaspargase;   Radiation: Radiation Therapy;   Drug: Thioguanine;   Drug: Vincristine Sulfate
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified January 2015

  • Condition:   Hyperlipidemia
    Interventions:   Drug: Bococizumab (PF-04950615; RN316);   Other: Placebo
    Sponsor:   Pfizer
    Recruiting - verified May 2015

  • Conditions:   Childhood Solid Neoplasm;   Recurrent Childhood Medulloblastoma;   Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor;   Recurrent Neuroblastoma
    Interventions:   Drug: Irinotecan Hydrochloride;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Drug: WEE1 Inhibitor MK-1775
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified February 2015

  • Condition:   Alzheimer's Disease
    Intervention:   Drug: T-817MA
    Sponsors:   Toyama Chemical Co., Ltd.;   Alzheimer's Disease Cooperative Study (ADCS)
    Recruiting - verified March 2015

  • Condition:   Constipation - Functional
    Interventions:   Drug: Lubiprostone;   Drug: Placebo
    Sponsors:   Sucampo AG;   Sucampo Pharma Americas, LLC;   Takeda
    Recruiting - verified May 2015

  • Conditions:   Stage II Childhood Anaplastic Large Cell Lymphoma;   Stage III Childhood Anaplastic Large Cell Lymphoma;   Stage IV Childhood Anaplastic Large Cell Lymphoma
    Interventions:   Drug: Brentuximab Vedotin;   Drug: Crizotinib;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Dexamethasone;   Drug: Doxorubicin Hydrochloride;   Drug: Etoposide;   Drug: Ifosfamide;   Other: Laboratory Biomarker Analysis;   Drug: Methotrexate
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified March 2015

  • Condition:   Central Retinal Vein Occlusion
    Interventions:   Drug: aflibercept;   Drug: bevacizumab
    Sponsors:   The EMMES Corporation;   National Eye Institute (NEI);   Milton S. Hershey Medical Center;   University of Wisconsin, Madison
    Recruiting - verified April 2015

  • Condition:   Hyperlipidemia
    Interventions:   Drug: Bococizumab (PF-04950615; RN316);   Other: Placebo
    Sponsor:   Pfizer
    Recruiting - verified May 2015

  • Condition:   Lymphoma, Non-Hodgkin
    Interventions:   Drug: Rituximab;   Drug: Lenalidomide;   Drug: Rituximab;   Drug: Placebo
    Sponsor:   Celgene Corporation
    Recruiting - verified May 2015

  • Conditions:   Untreated Childhood Anaplastic Astrocytoma;   Untreated Childhood Anaplastic Oligodendroglioma;   Untreated Childhood Brain Stem Glioma;   Untreated Childhood Giant Cell Glioblastoma;   Untreated Childhood Glioblastoma;   Untreated Childhood Gliosarcoma
    Interventions:   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Radiation: Radiation Therapy;   Drug: WEE1 Inhibitor MK-1775
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified March 2015

  • Conditions:   Schizophrenia;   Autism;   Bipolar Depression
    Intervention:   Drug: Lurasidone 20, 40, 60, 80 mg, flexibly dosed
    Sponsor:   Sunovion
    Recruiting - verified May 2015

  • Condition:   Schizophrenia
    Interventions:   Drug: Lurasidone 40 mg;   Drug: Lurasidone 80 mg;   Drug: Placebo 40 or 80 mg
    Sponsor:   Sunovion
    Recruiting - verified May 2015

  • Condition:   Anthracycline-induced Cardiotoxicity
    Intervention:  
    Sponsors:   The Hospital for Sick Children;   Canadian Institutes of Health Research  (CIHR);   Ontario Institute for Cancer Research;   Pediatric Oncology Group of Ontario;   C17 Council;   Ottawa Heart Institute Research Corporation;   Montreal Heart Institute;   McMaster Children's Hospital;   Children's Hospital of Eastern Ontario;   London Health Sciences Centre;   Children’s Hospital of Orange County;   Princess Margaret Hospital, Canada
    Recruiting - verified May 2015

  • Conditions:   Recurrent Adult Hodgkin Lymphoma;   Recurrent Childhood Hodgkin Lymphoma;   Refractory Childhood Hodgkin Lymphoma
    Interventions:   Drug: Brentuximab Vedotin;   Drug: Gemcitabine Hydrochloride;   Other: Laboratory Biomarker Analysis
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified March 2015

  • Condition:   Thromboembolism
    Intervention:   Drug: Apixaban
    Sponsors:   Bristol-Myers Squibb;   Pfizer
    Recruiting - verified September 2014

  • Condition:   Malignant Melanoma
    Intervention:   Biological: Ipilimumab
    Sponsor:   Bristol-Myers Squibb
    Recruiting - verified June 2014

  • Condition:   Parainfluenza
    Interventions:   Drug: DAS181 dry powder, formulation F02;   Drug: Lactose Placebo
    Sponsor:   Ansun Biopharma, Inc.
    Recruiting - verified May 2015

  • Condition:   Urinary Bladder, Neurogenic
    Interventions:   Drug: Fesoterodine PR 4 mg;   Drug: Fesoterodine PR 8 mg;   Drug: Fesoterodine PR 8 mg;   Drug: Oxybutynin;   Drug: Fesoterodine PR;   Drug: Fesoterodine BIC 2 mg;   Drug: Fesoterodine BIC 4 mg
    Sponsor:   Pfizer
    Recruiting - verified April 2015

  • Conditions:   Adult Acute Megakaryoblastic Leukemia;   Adult Acute Monoblastic Leukemia;   Adult Acute Monocytic Leukemia;   Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11;   Adult Acute Myeloid Leukemia With Maturation;   Adult Acute Myeloid Leukemia With Minimal Differentiation;   Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11;   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1;   Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLL;   Adult Acute Myeloid Leukemia Without Maturation;   Adult Acute Myelomonocytic Leukemia;   Adult Erythroleukemia;   Adult Pure Erythroid Leukemia;   Childhood Acute Erythroid Leukemia;   Childhood Acute Megakaryoblastic Leukemia;   Childhood Acute Monoblastic Leukemia;   Childhood Acute Monocytic Leukemia;   Childhood Acute Myeloid Leukemia With Maturation;   Childhood Acute Myeloid Leukemia Without Maturation;   Childhood Acute Myelomonocytic Leukemia;   Untreated Adult Acute Myeloid Leukemia;   Untreated Childhood Myeloid Neoplasm
    Interventions:   Drug: Asparaginase;   Drug: Bortezomib;   Drug: Cytarabine;   Drug: Daunorubicin Hydrochloride;   Drug: Etoposide;   Other: Laboratory Biomarker Analysis;   Drug: Mitoxantrone Hydrochloride;   Other: Pharmacological Study;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Drug: Sorafenib Tosylate
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified April 2015

  • Conditions:   Hematologic Malignancies;   Certain:;   Inherited Disorders of Metabolism;   Inherited Abnormalities of Erythrocyte Differentiation or Function;   Inherited Abnormalities of Platelets;   Disorders of the Immune System;   Histiocytic Disorders;   X-linked Lymphoproliferative Syndrome;   Primary Immunodeficiency Diseases;   Bone Marrow Failure;   Beta-thalassemia
    Intervention:   Drug: A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs)
    Sponsors:   Center for International Blood and Marrow Transplant Research;   National Marrow Donor Program
    Recruiting - verified May 2015

  • Conditions:   Recurrent Childhood Medulloblastoma;   Recurrent Childhood Pineoblastoma;   Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor
    Interventions:   Biological: Bevacizumab;   Drug: Irinotecan Hydrochloride;   Drug: Temozolomide
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified March 2015

  • Conditions:   B-cell Childhood Acute Lymphoblastic Leukemia;   Philadelphia Chromosome Positive Childhood Precursor Acute Lymphoblastic Leukemia;   Untreated Adult Acute Lymphoblastic Leukemia;   Untreated Childhood Acute Lymphoblastic Leukemia
    Interventions:   Drug: doxorubicin hydrochloride;   Drug: cytarabine;   Drug: vincristine sulfate;   Drug: dexamethasone;   Drug: pegaspargase;   Drug: methotrexate;   Drug: mercaptopurine tablet;   Drug: leucovorin calcium;   Drug: cyclophosphamide;   Drug: thioguanine;   Procedure: quality-of-life assessment;   Other: questionnaire administration;   Other: laboratory biomarker analysis
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified May 2015

  • Conditions:   Hepatoblastoma;   Stage I Childhood Hepatocellular Carcinoma;   Stage II Childhood Hepatocellular Carcinoma;   Stage III Childhood Hepatocellular Carcinoma;   Stage IV Childhood Hepatocellular Carcinoma
    Interventions:   Drug: Cisplatin;   Drug: Doxorubicin Hydrochloride;   Drug: Fluorouracil;   Drug: Irinotecan Hydrochloride;   Other: Laboratory Biomarker Analysis;   Procedure: Liver Transplantation;   Drug: Temsirolimus;   Procedure: Therapeutic Conventional Surgery;   Drug: Vincristine Sulfate
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified April 2015

  • Condition:   Leukemia
    Interventions:   Genetic: DNA analysis;   Genetic: RNA analysis;   Genetic: cytogenetic analysis;   Genetic: fluorescence in situ hybridization;   Genetic: gene expression analysis;   Genetic: microarray analysis;   Genetic: mutation analysis;   Genetic: polymerase chain reaction;   Genetic: polymorphism analysis;   Other: flow cytometry;   Other: laboratory biomarker analysis;   Other: pharmacological study
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified May 2015

  • Condition:   Heart Failure
    Intervention:   Device: ACUITY Spiral Left Ventricular Lead
    Sponsor:   Boston Scientific Corporation
    Recruiting - verified May 2015

  • Conditions:   Childhood Atypical Teratoid/Rhabdoid Tumor;   Childhood Central Nervous System Germ Cell Tumor;   Childhood Choroid Plexus Tumor;   Childhood Craniopharyngioma;   Childhood Grade I Meningioma;   Childhood Grade II Meningioma;   Childhood Grade III Meningioma;   Childhood High-grade Cerebral Astrocytoma;   Childhood Infratentorial Ependymoma;   Childhood Low-grade Cerebral Astrocytoma;   Childhood Oligodendroglioma;   Childhood Supratentorial Ependymoma;   Newly Diagnosed Childhood Ependymoma;   Recurrent Childhood Cerebellar Astrocytoma;   Recurrent Childhood Cerebral Astrocytoma;   Recurrent Childhood Ependymoma;   Recurrent Childhood Medulloblastoma;   Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor;   Recurrent Childhood Visual Pathway and Hypothalamic Glioma;   Recurrent Childhood Visual Pathway Glioma
    Intervention:   Other: cytology specimen collection procedure
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified May 2015

  • Conditions:   Disseminated Neuroblastoma;   Ganglioneuroblastoma;   Localized Resectable Neuroblastoma;   Localized Unresectable Neuroblastoma;   Regional Neuroblastoma;   Stage 4S Neuroblastoma
    Interventions:   Other: laboratory biomarker analysis;   Other: cytology specimen collection procedure
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified May 2015

  • Conditions:   Askin Tumor;   Localized Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
    Intervention:   Other: laboratory biomarker analysis
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified May 2015

  • Conditions:   Acute Undifferentiated Leukemia;   Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative;   Childhood Acute Lymphoblastic Leukemia;   Childhood Acute Myeloid Leukemia/Other Myeloid Malignancies;   Childhood Chronic Myelogenous Leukemia;   Chronic Lymphocytic Leukemia;   Hairy Cell Leukemia;   Juvenile Myelomonocytic Leukemia;   Mast Cell Leukemia;   Neoplasm of Uncertain Malignant Potential;   Prolymphocytic Leukemia;   Secondary Acute Myeloid Leukemia;   T-cell Large Granular Lymphocyte Leukemia;   Unspecified Childhood Solid Tumor, Protocol Specific
    Intervention:   Other: cytology specimen collection procedure
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified May 2015

  • Conditions:   Clear Cell Sarcoma of the Kidney;   Congenital Mesoblastic Nephroma;   Diffuse Hyperplastic Perilobar Nephroblastomatosis;   Rhabdoid Tumor of the Kidney;   Stage I Renal Cell Cancer;   Stage I Wilms Tumor;   Stage II Renal Cell Cancer;   Stage II Wilms Tumor;   Stage III Renal Cell Cancer;   Stage III Wilms Tumor;   Stage IV Renal Cell Cancer;   Stage IV Wilms Tumor;   Stage V Wilms Tumor
    Interventions:   Other: laboratory biomarker analysis;   Other: cytology specimen collection procedure
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified May 2015

  • Condition:   Sarcoma
    Intervention:   Other: biologic sample preservation procedure
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified May 2015

  • Condition:   Hepatic Veno-Occlusive Disease
    Interventions:   Drug: Defibrotide;   Drug: Defibrotide
    Sponsor:   Jazz Pharmaceuticals
    Recruiting - verified May 2015

  • Condition:   Idiopathic Thrombocytopenic Purpura
    Intervention:   Biological: IGIV3I Grifols 10%
    Sponsor:   Grifols Biologicals Inc.
    Recruiting - verified May 2015

  • Conditions:   Localized Resectable Neuroblastoma;   Localized Unresectable Neuroblastoma;   Regional Neuroblastoma;   Stage 4 Neuroblastoma;   Stage 4S Neuroblastoma
    Interventions:   Biological: Aldesleukin;   Biological: Dinutuximab;   Drug: Isotretinoin;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Other: Quality-of-Life Assessment;   Biological: Sargramostim
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified April 2015